Outputs (28)

Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI (2018)
Journal Article
Xing, Y., Sapuan, A., Dineen, R., & Auer, D. P. (2018). Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Movement Disorders, 33(11), 1792-1799. https://doi.org/10.1002/mds.27502

Background: Neuromelanin is a pigment with strong iron-chelating properties preferentially found in dopaminergic neurons of the substantia nigra, pars compacta (SNpc). Parkinson's disease is characterized by pronounced, MRI detectable neuromelanin lo... Read More about Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.

How do spatially distinct frequency specific MEG networks emerge from one underlying structural connectome? The role of the structural eigenmodes (2018)
Journal Article
Tewarie, P., Abeysuriya, R., Byrne, Á., O'Neill, G. C., Sotiropoulos, S. N., Brookes, M. J., & Coombes, S. (2019). How do spatially distinct frequency specific MEG networks emerge from one underlying structural connectome? The role of the structural eigenmodes. NeuroImage, 186, 211-220. https://doi.org/10.1016/j.neuroimage.2018.10.079

Functional networks obtained from magnetoencephalography (MEG) from different frequency bands show distinct spatial patterns. It remains to be elucidated how distinct spatial patterns in MEG networks emerge given a single underlying structural networ... Read More about How do spatially distinct frequency specific MEG networks emerge from one underlying structural connectome? The role of the structural eigenmodes.

Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancer: a pilot study for integration into treatment planning (2018)
Journal Article
Betts, H. M., O'Connor, R. A., Christian, J. A., Vinayakamoorthy, V., Foweraker, K., Pascoe, A. C., & Perkins, A. C. (2019). Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancer: a pilot study for integration into treatment planning. Nuclear Medicine Communications, 40(1), 73-78. https://doi.org/10.1097/MNM.0000000000000933

Background: Radical chemoradiotherapy is the primary treatment for head and neck cancers in many hospitals. Tumour hypoxia causes radiotherapy resistance, and is an indicator of poor prognosis for patients. Identifying hypoxia to select patients for... Read More about Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancer: a pilot study for integration into treatment planning.

Automated quality control for within and between studies diffusion MRI data using a non-parametric framework for movement and distortion correction (2018)
Journal Article
Bastiani, M., Cottaar, M., Fitzgibbon, S. P., Suri, S., Alfaro-Almagro, F., Sotiropoulos, S. N., …Andersson, J. (2019). Automated quality control for within and between studies diffusion MRI data using a non-parametric framework for movement and distortion correction. NeuroImage, 184, 801-812. https://doi.org/10.1016/j.neuroimage.2018.09.073

Diffusion MRI data can be affected by hardware and subject-related artefacts that can adversely affect downstream analyses. Therefore, automated quality control (QC) is of great importance, especially in large population studies where visual QC is no... Read More about Automated quality control for within and between studies diffusion MRI data using a non-parametric framework for movement and distortion correction.

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma (2018)
Journal Article
Grill, J., Massimino, M., Bouffet, E., Azizi, A. A., McCowage, G., Cañete, A., …Giangaspero, F. (2018). Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. Journal of Clinical Oncology, 36(10), https://doi.org/10.1200/JCO.2017.76.0611

Purpose
Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (... Read More about Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma.

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial (2017)
Journal Article
Bath, P. M., Christensen, L. M., Woodhouse, L. J., Bentsen, L., Appleton, J. P., Krarup Hansen, C., Beridze, M., Thomsen, T. T., Christensen, H., Kruuse, C., Dineen, R. A., Jensen, H. H., Duley, L., Hansen, S. S., England, T. J., Petrovic, V., Flaherty, K., Beridze, N., Havard, D., Kakabadze, N., …Farren, P. (2018). Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet, 391(10123), 850-859. https://doi.org/10.1016/S0140-6736%2817%2932849-0

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplat... Read More about Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.

NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy (2017)
Journal Article
Rossi, F., Geiszler, P. C., Meng, W., Barron, M., Prior, M., Herd-Smith, A., …Conforti, L. (2018). NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy. Behavioural Brain Research, 339, https://doi.org/10.1016/j.bbr.2017.11.030

NAD metabolism and the NAD biosynthetic enzymes nicotinamide nucleotide adenylyltransferases (NMNATs) are thought to play a key neuroprotective role in tauopathies, including Alzheimer’s disease. Here, we investigated whether modulating the expressio... Read More about NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.

Brain activation in response to personalized behavioral and physiological feedback from self-monitoring technology: pilot study (2017)
Journal Article
Whelan, M. E., Morgan, P. S., Sherar, L. B., Kingsnorth, A. P., Magistro, D., & Esliger, D. W. (2017). Brain activation in response to personalized behavioral and physiological feedback from self-monitoring technology: pilot study. Journal of Medical Internet Research, 19(11), Article e384. https://doi.org/10.2196/jmir.8890

Background: The recent surge in commercially available wearable technology has allowed real-time self-monitoring of behaviour (eg, physical activity) and physiology (eg, glucose levels). However, there is limited neuroimaging work (ie, functional mag... Read More about Brain activation in response to personalized behavioral and physiological feedback from self-monitoring technology: pilot study.

Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease (2017)
Journal Article
Akram, H., Sotiropoulos, S. N., Jbabdi, S., Georgiev, D., Mahlknecht, P., Hyam, J., Foltynie, T., Limousin, P., De Vita, E., Jahanshahi, M., Hariz, M., Ashburner, J., Behrens, T., & Zrinzo, L. (2017). Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease. NeuroImage, 158, https://doi.org/10.1016/j.neuroimage.2017.07.012

Objectives
Firstly, to identify subthalamic region stimulation clusters that predict maximum improvement in rigidity, bradykinesia and tremor, or emergence of side-effects; and secondly, to map-out the cortical fingerprint, mediated by the hyperdire... Read More about Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease.

Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome (2017)
Journal Article
Reckziegel, D., Bailey, H., Cottam, W. J., Tench, C. R., Mahajan, R. P., Walsh, D. A., …Auer, D. P. (in press). Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome. BMJ Open, 7(6), Article e014013. https://doi.org/10.1136/bmjopen-2016-014013

Introduction: Osteoarthritis (OA) pain is a major cause of long-term disability and chronic pain in the adult population. One in five patients does not receive satisfactory pain relief, which reflects the complexity of chronic pain and the current la... Read More about Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome.